Figure 2

Protective efficacy of S-910823 plus A-910823 in a mouse infection model. (a) Study schedule schematic. On 20 d or 21 d post-second immunization, female mice were intranasally infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Bodyweight and mortality were monitored daily. The lungs were harvested at 6 h, 1 d, 3 d, and 9 d or 10 d post-infection. (b) and (e) Bodyweight changes in mice after infection with QHmusX (b, n = 6) or TY-8–612 (e, n = 8). Bodyweight of only surviving mice was measured. Each point represents the mean bodyweight of the particular group of mice (error bars indicate standard error of mean). Statistical significance was measured using Dunnett’s multiple comparison test (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001). (c) Survival curves of mice after infection with QHmusX. Statistical significance was measured using the log-rank test (*P < 0.05 and **P < 0.005). (d) and (f) Infectious virus titers in mouse lungs at 6 h, 1 d, and 3 d post-infection with SARS-CoV-2 QHmusX (d, n = 4) and SARS-CoV-2 TY-8–612 (f, n = 5). The titers are expressed as median tissue culture infective dose (TCID₅₀)/g of tissue in VeroE6/TMPRSS2 cells. The circles represent the titers in individual mice. The bars represent the geometric mean titers (error bars indicate standard deviation). The dotted lines represent the lower limit of detection. Statistical significance was determined using Tukey’s multiple comparison test (*P < 0.05, **P < 0.01, and ****P < 0.0001).